These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 8629676)

  • 1. Long-term intraperitoneal deferoxamine for hemochromatosis.
    Swartz RD; Legault DJ
    Am J Med; 1996 Mar; 100(3):308-12. PubMed ID: 8629676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Long-term efficacy of subcutaneous administration of deferoxamine in patients with secondary hemochromatosis].
    Kobayashi M; Yano K; Fujisawa S
    Rinsho Ketsueki; 1996 Apr; 37(4):303-10. PubMed ID: 8847800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neonatal hemochromatosis: failure of deferoxamine therapy.
    Jonas MM; Kaweblum YA; Fojaco R
    J Pediatr Gastroenterol Nutr; 1987; 6(6):984-8. PubMed ID: 3681586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of iron overload with a disposable multi-day delivery system.
    Paolo C; Francesco S; Sergio A
    Am J Hematol; 1996 Jan; 51(1):95. PubMed ID: 8571948
    [No Abstract]   [Full Text] [Related]  

  • 5. High-dose intravenous desferrioxamine (DFO) delivery in four thalassemic patients allergic to subcutaneous DFO administration.
    Lombardo T; Ferro G; Frontini V; Percolla S
    Am J Hematol; 1996 Jan; 51(1):90-2. PubMed ID: 8571945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weekend very high-dose intravenous deferoxamine in children with transfusional iron overload.
    Nelson SC; Hennessy JM; McDonough EA; Guck KL
    J Pediatr Hematol Oncol; 2006 Mar; 28(3):182-5. PubMed ID: 16679946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of subcutaneous deferoxamine in a child with hemochromatosis associated with congenital dyserythropoietic anemia, type I.
    Smithson WA; Perrault J
    Mayo Clin Proc; 1982 May; 57(5):322-5. PubMed ID: 7078263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hemochromatotic cirrhosis complicating pyridoxine-sensitive hereditary sideroblastic anemia. Case report].
    Abadia R; Rochant H; Levy VG
    Ann Med Interne (Paris); 1983; 134(4):327-32. PubMed ID: 6614712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type 3 hemochromatosis and beta-thalassemia trait.
    Riva A; Mariani R; Bovo G; Pelucchi S; Arosio C; Salvioni A; Vergani A; Piperno A
    Eur J Haematol; 2004 May; 72(5):370-4. PubMed ID: 15059075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Adiastole caused by a secondary cardiac hemochromatosis. Successful treatment with an iron chelating agent].
    Baudouy P; Lombrail P; Azancot I; Piekarski A; Martin E; Slama R
    Arch Mal Coeur Vaiss; 1983 Oct; 76(10):1240-6. PubMed ID: 6418103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous intravenous deferoxamine infusion. Treatment of secondary hemochromatosis in adults.
    Blume KG; Beutler E; Chillar RK; Fahey JL; Sharkoff D; Zia PK
    JAMA; 1978 May; 239(20):2149-51. PubMed ID: 642157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of iron overload.
    Cohen A; Witzleben C; Schwartz E
    Semin Liver Dis; 1984 Aug; 4(3):228-38. PubMed ID: 6091277
    [No Abstract]   [Full Text] [Related]  

  • 13. Irreversible ocular toxicity from single "challenge" dose of deferoxamine.
    Bene C; Manzler A; Bene D; Kranias G
    Clin Nephrol; 1989 Jan; 31(1):45-8. PubMed ID: 2783668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [-Cardiomyopathy as the cause of death in genetic hemochromatosis-].
    von Herbay A; Niederau C; Pilichowska M; Reinecke P; Perings C; Vester E; Strohmeyer G; Häussinger D
    Z Gastroenterol; 1996 Mar; 34(3):178-82. PubMed ID: 8650971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Four-hour measurement of urinary iron excretion after deferoxine treatment: a rapid, simple method for study of iron excretion.
    Bonkovsky HL; Weber R; Aaron L
    Am J Gastroenterol; 1990 May; 85(5):554-7. PubMed ID: 2337058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Present aspects of the treatment of hemochromatosis (apropos of 100 observations)].
    Darnis F; Mossé A; Breauté C; Delorme ML
    Ann Med Interne (Paris); 1971 Dec; 122(12):1193-210. PubMed ID: 5151624
    [No Abstract]   [Full Text] [Related]  

  • 17. [Treatment and prevention of chronic iron overload (author's transl)].
    Brissot P; Bourel M; Simon M
    Gastroenterol Clin Biol; 1981 Dec; 5(12):1108-19. PubMed ID: 7319207
    [No Abstract]   [Full Text] [Related]  

  • 18. Quality of life related to oral versus subcutaneous iron chelation: a time trade-off study.
    Osborne RH; De Abreu Lourenço R; Dalton A; Houltram J; Dowton D; Joshua DE; Lindeman R; Ho PJ
    Value Health; 2007; 10(6):451-6. PubMed ID: 17970927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Temporary blindness in hemochromatosis].
    Sakić D; Zlatar P
    Ophthalmologica; 1974; 168(4):253-60. PubMed ID: 4837176
    [No Abstract]   [Full Text] [Related]  

  • 20. Reversible severe hereditary hemochromatotic cardiomyopathy.
    Madani TA; Bormanis J
    Can J Cardiol; 1997 Apr; 13(4):391-4. PubMed ID: 9141972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.